Krystal Biotech reports Q3 2026 results, VYJUVEK revenue up 30%, $400M buyback authorized
Krystal posted $127.3 million in third-quarter VYJUVEK sales, reported early KB113 tumor regression data in Gorlin syndrome patients, and set a $400 million share repurchase program.
SEC filing